NOV 13, 2018 7:46 AM PST

Clinical Trial Drug For a Rare Neurodegenrative Disease Proven Unsuccessful

WRITTEN BY: Nouran Amin

Niemann-Pick type C (NPC) is a rare and fatal neurodegenerative disease. Symptoms of the condition include loss of balance, difficulty swallowing, seizures, and cognitive disabilities. These symptoms are due to an impaired ability to properly metabolize cholesterol.

Seeking treatment for NPC, a recent drug was placed in a key clinical trial for 56 affected children and youth. The drug, VTS-270, brought disappointing results when it was found to perform no differently than the placebo and “did not show a statistically significant separation,” says Steven Romano, the executive vice president of Mallinckrodt Pharmaceutical and chief scientific officer. However, the condition did not progress in both groups during the 1-year study.

“But importantly, neither did [patients in the active or placebo arms of the trial] show disease progression as would have been anticipated in the neurodegenerative condition over 52 weeks of observation,” explains Romano.

VTS-270 consists of a doughnut-shaped sugar molecule called a cyclodextrin that was spinally injected into the cerebrospinal fluid of the brain.

The chemical structure of VT2-270 (2-hydroxypropyl-β-cyclodextrin (HPβCD))

Image Credit: PLOS ONE

The drug showed positive results in animal models of the diseases but not in children during the one year study. Such results prompted other researchers who have expertise in rare diseases to suggest that the trial’s use of a traditional double-blind and randomized controlled trials may not be the best tool in such condition.

“This is a disappointing result but a very important one. The question I have is: Is it truly the case that this agent is not effective, or is the result the consequence of a trial design that in retrospect might have been better?” says Marc Patterson, a child neurologist who has been conducting NPC research and treating NPC-affected children for over 30 years.

Since NPC is a slow progressive disease, Patterson believe that the drug may have been successful if the clinical trial was much longer than the 1-year study. Patterson argues that this particular study raises issues regarding FDA’s approval time in clinical trials involving rare diseases.

“We’ll need to look at those open-label treatment patients and see if there’s any difference that gradually accrues over the course of that additional treatment period,” says Romano.

Source: Science Magazine

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 17, 2019
Cell & Molecular Biology
DEC 17, 2019
A New Tool for Assessing the Impact of Drugs on Single Cells
When scientists assess the impact of a treatment like a drug on cells, they usually generally rely on large populations of cells to find general trends....
DEC 27, 2019
Microbiology
DEC 27, 2019
Using a Cancer Drug to Fight Antibiotic-Resistant Pathogens
It takes a long time for a drug to be approved for use in humans; repurposing existing drugs is one way to get around that hurdle....
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Can Silica Treat Obesity and Diabetes?
Silica particles, specifically ‘mesoporous silica particles (MSPs)’ are engineered molecular traps that may provide a breakthrough treatment op...
JAN 16, 2020
Cancer
JAN 16, 2020
FLASH proton therapy: faster and more effective
A new technique called FLASH proposes a new type of radiation therapy. The technique is composed of an ultra-high dose rate of radiotherapy and uses electr...
JAN 20, 2020
Cell & Molecular Biology
JAN 20, 2020
Using Modified Red Blood Cells As a Drug Delivery System
For a drug to be effective, it has to get to the right place to exert its impact....
FEB 10, 2020
Drug Discovery & Development
FEB 10, 2020
Drug Prevents Coronavirus in Monkeys
An antiviral drug successfully prevented Middle East respiratory syndrome coronavirus (MERS-CoV) in infected rhesus macaques. The drug, Remdesivir, was adm...
Loading Comments...